RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147.

RBC Capital maintains Outperform rating on Abbott Laboratories (ABT) with a price target of $147. The firm sees strong single-digit revenue and double-digit EPS growth potential due to Abbott's positive healthcare utilization, diabetes brand growth, and favorable trends in diagnostics. Abbott is a leading global healthcare company with a range of products including branded generic medications, medical devices, diagnostics, and nutritional items.

RBC Capital has maintained its Outperform rating on Abbott Laboratories (ABT) while raising its price target to $147. The firm underscores Abbott’s robust single-digit revenue growth and double-digit EPS growth potential. These positive projections are attributed to Abbott’s strong healthcare utilization, the growth of its diabetes brand, and favorable trends in diagnostics.

Abbott Laboratories, a leading global healthcare company, offers a diverse range of products, including branded generic medications, medical devices, diagnostics, and nutritional items. The firm's positive outlook is bolstered by the company's strong business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals.

RBC Capital’s sustained belief in Abbott Laboratories as the best-performing large-cap in its coverage year-to-date is further enhanced by the company's less elective nature of its medical device portfolio. This characteristic provides a stable revenue stream, particularly in the face of potential economic downturns.

Reference List:
[1] https://www.marketscreener.com/quote/stock/ABBOTT-LABORATORIES-11506/consensus/
[2] https://finance.yahoo.com/news/rbc-capital-sees-strong-growth-054202287.html
[3] https://www.marketscreener.com/news/daiwa-securities-adjusts-abbott-laboratories-price-target-to-134-from-133-maintains-outperform-ra-ce7c5cddd881f52c